Portal de Periódicos da CAPES

Identification of Metastasis-Associated Receptor Tyrosine Kinases in Non–Small Cell Lung Cancer

2005; American Association for Cancer Research; Volume: 65; Issue: 5 Linguagem: Inglês

10.1158/0008-5472.can-04-3388

1538-7445

Carsten Müller‐Tidow, Sven Diederichs, Etmar Bulk, Thorsten Pohle, Björn Steffen, Joachim Schwäble, Sylvia Plewka, Michael Thomas, Ralf Metzger, Paul M. Schneider, Christian Brandts, Wolfgang E. Berdel, Hubert Serve,

Cancer-related gene regulation

Abstract Development of distant metastasis after tumor resection is the leading cause of death in early-stage non–small cell lung cancer (NSCLC). Receptor tyrosine kinases (RTK) are involved in tumorigenesis but only few RTKs have been systematically studied in NSCLC. Here, we provide quantitative real-time reverse transcription-PCR expression data of all RTKs (n = 56) in primary tumors of 70 patients with early-stage (I-IIIA) NSCLC. Overall, 33 RTKs were expressed in at least 25% of the patients. Several RTKs were significantly expressed higher in tumors that ultimately metastasized. The hazard risk for metastasis development in stage I/II disease was increased at least 3-fold for tumors with high expression levels of insulin receptor, neurotrophic tyrosine receptor kinase 1, epidermal growth factor receptor, ERBB2, ERBB3, platelet-derived growth factor receptor β, fibroblast growth factor receptor 1, or leukocyte tyrosine kinase. Relative risks were reduced 3-fold by expression of EPHB6 or DKFZ1. Three members of the epidermal growth factor receptor family were associated with a high risk of metastasis, emphasizing the validity of our data. High ERBB3 expression was significantly associated with decreased survival. Taken together, our genome-wide RTK expression map uncovered the previously unknown value of several RTKs as potential markers for prognosis and metastasis prediction in early-stage NSCLC. The identified RTKs represent promising novel candidates for further functional analyses.